Preanalgesic Effect of Gabapentin in Total Knee Repair
Information source: Presbyterian Hospital of Dallas
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain
Intervention: Gabapentin (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Presbyterian Hospital of Dallas Official(s) and/or principal investigator(s):
Rob Hutchison, Principal Investigator, Affiliation: Presbyterian Hospital of Dallas
Overall contact:
Rob Hutchison, PharmD, Phone: 214-345-2493, Email: robhutchison@texashealth.org
Summary
The purpose of this study is to determine whether gabapentin, as a one time administration
prior to a total knee replacement procedure, has opioid sparing effects and a reduction in
pain scores.
Clinical Details
Study design: Non-Randomized, Open Label, Placebo Control, Single Group Assignment
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients undergoing total knee replacement who received pain management by the
following modality:
- Intravenous patient-controlled analgesia (IV-PCA) opioid
- Local femoral nerve block with 1. 5% mepivacaine 20 ml and 0. 5% ropivacaine 20 ml
Exclusion Criteria:
- Age < 18 years old
Locations and Contacts
Rob Hutchison, PharmD, Phone: 214-345-2493, Email: robhutchison@texashealth.org
Presbyterian Hospital of Dallas, Dallas, Texas 75231, United States; Recruiting
Rob Hutchison, Phone: 214-345-2493, Email: robhutchison@texashealth.org
Denise Stamos, Phone: 214-345-2966, Email: denisestamos@texashealth.org
William Tucker, Principal Investigator
Jeffrey Pirinelli, Sub-Investigator
Joy Aguwa, Sub-Investigator
Additional Information
Last updated: February 27, 2007
|
